An Economic Crisis of Chronic Illnesses
We know medical costs lead to personal debt. Yet we continue adding to the costs, treating patients more and more....
Why is it Tough to Treat a Cough?
Coughs are everywhere this time of the year. They appear to be both harmless yet persistent, which make coughs particularly...
How the CDC and FDA Really Work
The CDC recently announced that it is evaluating its current organizational structure. We hope this leads to much needed changes,...
A Comment on the CDC’s Commentary
For two months, the CDC allowed public comments on its draft revision of the opioid prescribing guidelines. They reveal that...
Clinical Trial Meets Patient Advocacy
Clinical trials represent the science in healthcare. It is how we obtain new medical information. But to advance our knowledge...
Why the Opioid Epidemic is Poorly Reported
Few medical crises as large as the opioid epidemic have been so poorly reported. We present the results from our...
Lack of Research Over Long COVID
COVID-19 is now two years old. Along the way, it transitioned from an acute to a chronic condition. In the...
Healthcare Venture Growth Rarely Becomes Profitable
Growth for successful healthcare startups is defined financially. In reality, growth should be defined by clinical improvements, which is less...
Mapping Shifts in Healthcare Labor Markets
For how much we discuss staffing shortages and limited access to care, we have a poor sense of the labor...
The Actual Cost of COVID-19
In between conspiracy and accounting resides the truth about the financial impact of COVID-19. As a systemic risk, it is...
Much Ado About Aduhelm
The data supporting Aduhelm are scant at best. But that did not stop its manufacturer from releasing additional data, showing...
Why Pregnant People Should Get Vaccinated For COVID-19
Pregnancy is often a time of sweet anticipation. But the ongoing pressure to make the right decisions for the health...
Videos
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more